Acadia Pharmaceuticals (ACAD) Operating Expenses (2010 - 2026)

Acadia Pharmaceuticals' Operating Expenses history runs 17 years deep, the most recent figure standing at $272.7 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 21.18% year-over-year to $272.7 million; the TTM figure through Mar 2026 stood at $1.0 billion (up 33.22% YoY), while the FY2025 annual figure was $966.7 million, up 32.97% from the prior year.
• Operating Expenses was $272.7 million for Q1 2026 at Acadia Pharmaceuticals, up from $266.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $272.7 million in Q1 2026 to a low of $106.1 million in Q4 2024.
• Historically, Operating Expenses has averaged $206.3 million across 5 years, with a median of $211.5 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses sank 45.89% in 2024, then jumped 151.27% in 2025.
• A 5-year view of Operating Expenses shows it stood at $182.6 million in 2022, then grew by 7.42% to $196.1 million in 2023, then tumbled by 45.89% to $106.1 million in 2024, then surged by 151.27% to $266.6 million in 2025, then advanced by 2.28% to $272.7 million in 2026.
• The last three Operating Expenses figures came in at $272.7 million (Q1 2026), $266.6 million (Q4 2025), and $242.9 million (Q3 2025), per Business Quant data.